| Name | Title | Contact Details |
|---|
Saltwhistle Technology is a Chester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company`s cutting-edge platform was spun out of the labs of Vividion`s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA.
Rapid Micro Biosystems accelerates the detection of microbial contamination in the manufacture of pharmaceuticals, biologics, medical devices, and personal care products. The company`s Growth Direct™ Platform—the first and only growth-based platform to fully automate traditional microbial testing—detects contamination more quickly, delivering compelling economic benefits while improving quality control processes. The Growth Direct platform replaces slow, error-prone, manual processes, allowing manufacturers to accelerate timelines, maximize capacity, and reduce operational risk and downtime, all while maintaining the highest standards of data integrity. Rapid Micro Biosystems is dedicated to providing groundbreaking technology and products to support biomanufacturing companies in their mission to deliver the highest possible quality products for improved patient outcomes. Rapid Micro Biosystems is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Germany and the Netherlands.
Jasper Clinical Research and Development is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.